Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple therapy shows promise in shrinking sarcomas before surgery

NCT ID NCT06128863

Disease control Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining an immunotherapy drug (pembrolizumab) with another immune-boosting protein (eftilagimod alpha) and radiation therapy can shrink soft tissue sarcomas before surgery. About 40 adults with high-risk, non-spread sarcomas will receive this combination, then have their tumor removed to see how much of it has been destroyed. The goal is to improve outcomes, but ongoing monitoring and potential long-term treatment may still be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary or locally recurrent deep-seated extremities, girdles and/or superficial trunk (thoracic or abdominal wall) soft tissue sarcoma * Grade 2 or 3 tumors according to Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC); * Size of the primary tumor \>5 cm at instrumental staging (CT, MRI), or locally recurrent of any size; * Measurable disease based on RECIST 1.1; * Non-metastatic disease; Exclusion Criteria: * Ewing sarcoma, Alveolar and embryonal rhabdomyosarcoma * Previous treatment with eftilagimod alfa, anti-PD-1 or anti-PD-L1; * Prior radiotherapy to tumor-involved sites;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immunotherapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immunotherapy Neoadjuvant Radiation therapy Sarcoma,soft tissue

Contacts and locations

Locations

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, 00-738, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.